07:00 , Apr 17, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

AstraZeneca plc had a busy March, announcing five new public-private partnerships and the launch of its Open Innovation website to list additional partnership opportunities ( see "Selected public-private partnerships for March 2014"). One of the...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

Bicoll GmbH, Charite - Universitaetsmedizin Berlin, German Federal Ministry of Education and Research neurology news

Bicoll and Charite's Horst-Goertz-Endowment Institute for the Theory, History and Ethics of Chinese Life Sciences said their joint Anti- Epileptic Compounds Leveraging Ancient Prescriptions (EPICLEAP) project received partial funding from the ministry. The partners are...
07:00 , Oct 10, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Focusing the BRAIN The NIH 's BRAIN initiative has developed a road map for its near-term research priorities, chief among which is conducting a census of brain cells. Whether the ambitious, decades-long project will be...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Company News

EpimiRNA Consortium neurology news

The consortium received €11.5 million ($15.4 million) in funding from the EU's Framework 7 Programme (FP7) to investigate molecular mechanisms, diagnostics and treatments for epilepsy. The consortium will focus on the effects of microRNA on...
07:00 , May 16, 2011 |  BC Week In Review  |  Company News

Biocoll GmbH, Genfit, University of Freiburg deal

The partners began the OLNORME II program to develop candidates targeting an undisclosed nuclear orphan receptor from plant metabolites to prevent and treat cardiovascular, metabolic and neurodegenerative diseases, including atherosclerosis, Type II diabetes, obesity and...
08:00 , Jan 29, 2007 |  BC Week In Review  |  Company News

Genfit, Bicoll GmbH, Merck KGaA, University of Freiburg deal

Genfit partnered with Bicoll and the university to discover ligands for undisclosed orphan nuclear receptors to treat cardiovascular and metabolic diseases. The 2.5-year deal will be sponsored by EurotransBio, which is an industry development consortium...